Theravance Biopharma

Medicines That Make a Difference®

Theravance Biopharma, Inc.
KOL Event

Standard and Exploratory Treatments for Ulcerative Colitis

Agenda

- Opening Remarks
- Optimizing First-Line Treatment in Ulcerative Colitis
- JAK Inhibitor Mechanism: How it Differs from Current Treatments
- GI-Targeted JAK Inhibition for Ulcerative Colitis
- Q&A
- Closing Remarks

The landscape of treatments in ulcerative colitis

Maria T. Abreu, MD
University of Miami Miller School of Medicine
Miami, Florida

UHealth
UNIVERSITY OF MIAMI HEALTH SYSTEM

UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

Disclosures

- Abbvie Laboratories
- Janssen
- Prometheus Laboratories
- Eli Lilly
- Takeda
- Celgene Corporation
- UCB
- Theravance Biopharma
- Pfizer

UHealth
UNIVERSITY OF MIAMI HEALTH SYSTEM

UNIVERSITY OF MIAMI
MILLER SCHOOL
of MEDICINE

Inflammatory Bowel Diseases

Ulcerative Colitis

Confined to the colon



Crohn's Disease

Any portion of the GI tract





Frequency of Involvement

Most *Least*

Endoscopic Severity of Ulcerative Colitis



NORMAL



MILD

Diminished vascular markings, mild erythema, granularity, and friability



MODERATE

Marked erythema, absent vascular markings, contact friability, no ulcers



SEVERE

Spontaneous bleeding, ulcers

Ulcerative Colitis





- Mucosal inflammation
- Microulcerations
- Crypt abscesses
- Branched glands
- Decreased # of mucosal glands

Current targets of biologics



4 anti-TNFs
1 anti-IL-12/23 (ustekinumab)

Modulating the immune system

Trafficking



Anti-α4β7
Anti-α4
S1P receptor agonists (Ozanimod)

Corticosteroids

Proliferation

Cyclosporine
Tacrolimus



6-MP/AZA
Methotrexate

T cell regulation



Anti-cytokines
Mongersen
JAK inhibitors





ibitor

intracellular
-JAK/STAT

nds multiple
s including:
12 (JAK3)

3 inhibitor
and
tis

hibitor,
's disease

JAK inhibitor

TNF, tumor necrosis factor; RA, rheumatoid arthritis

Shuai K et al. *Nat Rev Immunol.* 2003;11:900.

Sequential Therapies for UC



Therapy is stepped up according to severity at presentation or failure at prior step

Anti-TNFs for ulcerative colitis

Infliximab



Chimeric monoclonal antibody (75% human IgG_1 isotype)

Adalimumab



Human recombinant antibody (100% human IgG_1 isotype)

Golimumab



Human recombinant antibody (100% human IgG_1 isotype)

Mouse
Human
PEG, polyethylene glycol.

Infliximab in UC: The ACT1 and ACT2 Trials



Rutgeerts P et al. *N Engl J Med.* 2005;353:2462-2476.

Adalimumab in UC

40% of patients in trial were previously anti-TNF exposed



Includes anti-TNF naive patients
*Per partial Mayo score; †Per Mayo score;
[a]*P*<.001; [b]*P*<.05

UC SUCCESS study (SONIC for UC)



*P<.05 compared to IFX; #P<.05 compared to AZA

Panccione R et al. DDW 2011; Abstract 835

Secondary End Point: Mucosal Healing at Week 16

Mayo endoscopy subscore of 0 or 1



AZA=azathioprine; IFX=infliximab.

Panaccione R et al. *J Crohns Colitis.* 2011;5:S8. Abstract 13.

Strategies to inhibit leukocyte trafficking to the intestine



CCR9 blockade

Anti-integrin

GEMINI I: Vedolizumab in Ulcerative Colitis



PBO, placebo; VDZ, vedolizumab; Mean Δ % (95% CI) = mean percentage point difference VDZ vs PBO (95% confidence interval).

Feagan BG et al. NEJM 2013; 369 (8): 699-710.

GEMINI I: Vedolizumab in Ulcerative Colitis

Primary Outcome: Maintenance ITT Population



Adjusted difference, percentage points (95% CI)	Clinical Remission
VDZ Q8W vs PBO	26.1 (14.9, 37.2)
VDZ Q4W vs PBO	29.1 (17.9, 40.4)

Feagan BG et al. NEJM 2013; 369 (8): 699-710.

CS, corticosteroid; PBO, placebo; VDZ, vedolizumab.

Eucalyptus: Etrolizumab (Rhumab Beta7) for Induction of Remission in Moderate to Severe Ulcerative Colitis

- **Background:**
  - Blocks β7 subunit (α4β7 and αEβ7)
  - No CNS penetration
  - Phase 11 randomized double-blind placebo-controlled trial
- **Methods:**
  - Loading (420 mg at week 0, 300 mg at weeks 2, 4, 8): 100 mg at weeks 0, 4, 8: Placebo



- **Conclusion:**
  - Lower dose (100 mg) of etrolizumab is well tolerated and potentially effective

Vermeire S, et al. Presented at DDW; May 18, 2013. Abstract 159.

Or can you sequester the T cells (and B cells) so they cannot get to the gut

- Ozanimod (RPC1063) is an oral S1P receptor modulator (improved from fingolimod for MS)
- Causes sequestering of auto-reactive lymphocytes in the lymph node (Hotel California)
- Protective immunity may be preserved because effector memory T cells do not circulate through the lymph nodes



Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis





Sandborn, W. et al. N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248.

Key Adhesion Molecule Interactions



α_4-Integrins: required for firm adhesion to and migration across endothelium

Natalizumab

Vedolizumab

Upregulated by cytokines

Anti-MAdCAM

MAdCAM-1 = mucosal addressin cell adhesion molecule-1; VCAM-1 = vascular cell adhesion molecule-1

Berlin C et al. *Cell.* 1995;80(3):413; Alon R et al. *J Cell Biol*. 1995;128(6):1243

Unmet needs with current biologics in ulcerative colitis

- High attrition of anti-TNF effect (immunogenicity + mechanistic escape)
  - 10-20% per year, not counting need to increase dose
- Patients with co-morbidities, e.g. MS, cancer
- Patients with anti-TNF side-effects (psoriaform rash)
- Slow onset of action (vedolizumab)
- Systemic effects for mucosal disease
- Protein-based biologics benefit from combination therapy with immunomodulators
- IV and subq preparations (patients hate this)

Topically acting therapies work in ulcerative colitis



Finding the Right Mechanism for the Right Patient



JAK Inhibitor Mechanism: How it Differs from Current Treatments

Brian G. Feagan MD
Professor of Medicine, Epidemiology and Biostatistics
Senior Scientific Director, Robarts Clinical Trials Inc.
Western University
London, Ontario, Canada

Cytokines Signal via the JAK-STAT Pathway



Signaling selectivity may be achieved, in part, by combinations of multiple JAKs (4) activating multiple STATS (7)

O'Shea JJ et. al. Annu. Rev. Med. 2015

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 AUGUST 9, 2012 VOL. 367 NO. 6

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Roy Fleischmann, M.D., Joel Kremer, M.D., John Cush, M.D., Hendrik Schulze-Koops, M.D., Ph.D., Carol A. Connell, Ph.D., John D. Bradley, M.D., David Gruben, Ph.D., Gene V. Wallenstein, Ph.D., Samuel H. Zwillich, M.D., and Keith S. Kanik, M.D., for the ORAL Solo Investigators*

ABSTRACT

BACKGROUND

Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis.

METHODS

In this phase 3, double-blind, placebo-controlled, parallel-group, 6-month study, 611 patients were randomly assigned, in a 4:4:1:1 ratio, to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, placebo for 3 months followed by 5 mg of tofacitinib twice daily, or placebo for 3 months followed by 10 mg of tofacitinib twice daily. The primary end points, assessed at month 3, were the percentage of patients with at least a 20% improvement in the American College of Rheumatology scale (ACR 20), the change from baseline in Health Assessment Questionnaire–

From the Metroplex Clinical Research Center (R.F.) and Baylor Research Institute (J.C.) — both in Dallas; the Center for Rheumatology, Albany Medical College, Albany, NY (J.K.); the Division of Rheumatology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany (H.S.-K.); and Pfizer, Groton, CT (C.A.C., J.D.B., D.G., G.V.W., S.H.Z., K.S.K.). Address reprint requests to Dr. Fleischmann at the Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75231, or at rfleischmann@arthdocs.com.



Primary Efficacy Analysis

- Panel A: the percentage of patients with at least a 20% improvement in the American College of Rheumatology scale (ACR 20)
- Panel B: the least-squares mean change from baseline in the score on the Health Assessment Questionnaire–Disability Index (HAQ-DI)
- Panel C: the percentage of patients with a score of less than 2.6 on the Disease Activity Score for 28-joint counts, based on the erythrocyte sedimentation rate

Fleischmann R et al. N Engl J Med 2012;367:495-507.

The Evolution of JAK Inhibitors



Tofacitinib in UC: Clinical Response Rate at Week 8

- Difference from placebo (90% CI) in estimated clinical response rate:
  - Tofacitinib 10 mg BID treatment group: 26.9% (17.0, 36.8)
  - Tofacitinib 15 mg BID treatment group: 38.2% (25.3, 51.2)



BID, twice daily; CI, confidence interval

Sandborn WJ. New England J Med 2012

Phase 3Tofacitinib Program



Patients

- ≥18 years old, moderately to severely active ulcerative colitis (Mayo score ≥6; rectal bleeding subscore ≥1; centrally-read endoscopic subscore ≥2 (colonoscopy or flexible sigmoidoscopy)
- Prior failure or intolerance to ≥1 of: corticosteroids, azathioprine, 6-MP or TNF inhibitors (TNFi)
- Washout: TNFi, 8 weeks; immunosuppressants, 2 weeks
- Concomitant corticosteroids: max dose 25 mg/day; stable during the study

[a]Final complete efficacy assessment at week 8/52. Treatment continued up to week 9/53; [b]Patients in remission at OLE baseline: 5 mg BID; all others:10 mg BID
6-MP, 6-mercaptopurine; TNF, tumour necrosis factor

Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Demographics and Baseline Characteristics

	OCTAVE Induction 1		OCTAVE Induction 2	
	Placebo N=122	Tofacitinib 10 mg BID N=476	Placebo N=112	Tofacitinib 10 mg BID N=429
Gender, % female	36.9	41.8	50.9	39.6
Age, years[a]	41.8 (15.3)	41.3 (14.1)	40.4 (13.2)	41.1 (13.5)
Geographic region, % European	59.0	59.9	56.3	58.0
Disease duration, years[a]	8.4 (7.6)	8.3 (7.1)	7.7 (6.3)	8.0 (6.9)
Total Mayo score[a]	9.1 (1.4)	9.0 (1.4)	8.9 (1.5)	9.0 (1.5)
Extent of disease, %				
Proctosigmoiditis	15.6	13.7	14.4	15.7
Left-sided colitis	30.3	33.3	35.1	34.8
Extensive colitis or pancolitis	54.1	53.1	50.5	49.3
Prior TNFi treatment, %	53.3	53.4	58.0	54.5
Prior TNFi failure, %	52.5	51.1	53.6	51.7
Prior immunosuppressant failure, %	68.0	75.6	67.0	70.2
Prior corticosteroid failure, %	80.3	73.5	74.1	70.6
Oral corticosteroid use, %	47.5	45.0	49.1	46.2

Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Primary Endpoint: Remission at Week 8



Data are full analysis set with non-responder imputation, central read
Significance vs placebo calculated by Cochran-Mantel-Haenszel chi-square test

Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Key Secondary Endpoint: Mucosal Healing at Week 8



Data are full analysis set with non-responder imputation, central read
Significance vs placebo calculated by Cochran-Mantel-Haenszel chi-square test

Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Efficacy by TNF Inhibitor Exposure



Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Summary of Adverse Events

	OCTAVE Induction 1		OCTAVE Induction 2	
	Placebo N=122	**Tofacitinib 10 mg BID N=476**	**Placebo N=112**	**Tofacitinib 10 mg BID N=429**
Adverse events, n (%)	73 **(59.8%)**	269 **(56.5%)**	59 **(52.7%)**	232 **(54.1%)**
Most frequently occurring adverse events by preferred term, n (%)				
Headache	10 **(8.2%)**	37 **(7.8%)**	9 **(8.0%)**	33 **(7.7%)**
Nasopharyngitis	9 **(7.4%)**	39 **(8.2%)**	4 **(3.6%)**	21 **(4.9%)**
Serious adverse events, n (%)	5 **(4.1%)**	16 **(3.4%)**	9 **(8.0%)**	18 **(4.2%)**
Discontinuations due to adverse events, n (%)	2 **(1.6%)**	18 **(3.8%)**	8 **(7.1%)**	17 **(4.0%)**
Deaths, n (%)	0 **(0.0%)**	1 **(0.2%)[a]**	0 **(0.0%)**	0 **(0.0%)**

[a]Dissecting aortic aneurysm; died on Study Day 31: This subject was a 40-year-old white male (Ukraine) without relevant past medical history or known risk factors for aortic dissection. Autopsy confirmed aortic aneurysm dissection and cardiac tamponade. The event was assessed as not related to study drug by the investigator

Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Adverse Events

	OCTAVE Induction 1		OCTAVE Induction 2	
	Placebo N=122	Tofacitinib 10 mg BID N=476	Placebo N=112	Tofacitinib 10 mg BID N=429
Infections, n (%)[a]	19 **(15.6%)**	111 **(23.3%)**	17 **(15.2%)**	78 **(18.2%)**
Herpes zoster[b]	1 **(0.8%)**	3 **(0.6%)**	0 **(0.0%)**	2 **(0.5%)**
Serious infections, n (%)[c]	0 **(0.0%)**	6 **(1.3%)**	0 **(0.0%)**	1 **(0.2%)**
Cardiovascular events, n (%)[d]	0 **(0.0%)**	2 **(0.4%)**	0 **(0.0%)**	1 **(0.2%)**
Intestinal perforations, n (%)[e]	0 **(0.0%)**	1 **(0.2%)**	1 **(0.9%)**	0 **(0.0%)**
Malignancies, n (%)[d]	0 **(0.0%)**	1 **(0.2%)**	0 **(0.0%)**	1 **(0.2%)**
Non-melanoma skin cancer	0 **(0.0%)**	1 **(0.2%)**	0 **(0.0%)**	1 **(0.2%)**

[a]There were no cases of tuberculosis in either study; [b]None were reported as serious adverse events; [c]Serious infections were: anal abscess, cellulitis, *clostridium difficile* infection, febrile infection, otitis externa, pneumonia, furuncle, all n=1; [d]Per an external independent adjudication committee based on pre-defined adjudication criteria; [e]Preferred term

Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Percent Change from Baseline in Clinical Laboratory Parameters Over Time



Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Conclusions

- Tofacitinib demonstrated significantly greater efficacy vs placebo as induction therapy for patients with ulcerative colitis in two replicate studies
- The observed treatment effects were similar between TNFi-experienced and TNFi-naïve patients
- Improvements in Partial Mayo score as early as Week 2 supported early onset of treatment effect
- No new or unexpected safety signals were observed

Sandborn WJ et al. ECCO, Amsterdam, March 16–19 2016. Presentation No. OP019

Tofacitinib Provides Small, Modest Treatment Effects for Induction of CD Remission

- Methods
  - Multicenter phase 2b study of moderate-severe CD patients (CDAI=220-450), n=280
  - Placebo , tofacitinib 5 mg BID, tofacitinib 10 mg BID
  - Primary endpoint: clinical remission (CDAI<150) at week 8
  - Secondary endpoints: Clinical response; Changes in CDAI, CRP, fecal calprotectin over time
- Results
  - Compared to placebo, tofacitinib does not significantly increase clinical remission



- **Tofacitinib does reduce CDAI scores and CRP concentration from baseline compared to placebo**

Panes J, et al. Presented at DDW; May 24, 2016. Abstract 855.

Tofacitinib Not Significantly More Effective than Placebo at Maintaining Response in CD

- Methods
  - Phase 2b study of 26 week maintenance therapy of moderate-severe CD (placebo-59, 5 mg BID-60, 10 mg BID-61)
  - Primary endpoint: Clinical response (CDAI 100) or clinical remission at wk 26
  - Secondary endpoints: Clinical remission/response, FCP, CRP, CDAI over time
- Results
  - Tofacitinib 10 mg BID with higher proportion of patients maintaining clinical response, but no significant difference to placebo
  - Significant decrease in CRP and fecal calprotectin with higher dose tofacitinib



D'Haens G, et al. Presented at DDW; May 24, 2016. Abstract 856.

Filgotinib is safe and effective for treatment of moderate to severe Crohn's disease

- Filgotinib: a selective once daily dose JAK1 inhibitor
- Tested for efficacy in 10 week multicenter/multinational European study: FITZROY

- **No concomitant TNFi or IMM allowed**
- **Awaiting maintenance, endoscopic data**
- **First Jak1 inhibitor safe/effective in Crohn's**



Vermeire S, et al. Presented at DDW; May 24, 2016. Abstract 812c.

Multiple Agents Under Development

- JAK1 selectivity ?

- Selective JAK-inhibitors= better therapeutic index ?
  - Greater efficacy (selectivity may allow dose escalation)
  - Improved safety profile

- Local delivery?

Conclusions

- JAK kinase inhibitors have fulfilled POC in both UC and CD
- Adverse event profile is acceptable but could be improved
- Whether selective JAK 1 inhibition will provide a therapeutic advantage is unknown
- Potential advantages: oral administration, no immunogenicity and lower cost of goods
- Gut selectivity ???

Theravance Biopharma

Medicines That Make a Difference®

GI-Targeted JAK Inhibition for Ulcerative Colitis

Dr. Brett Haumann
Chief Medical Officer

Cautionary Statement Regarding Forward-Looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to differ materially from the forward-looking statements or projections.

Examples of forward-looking statements in this presentation include statements relating to the company's business plans and objectives, including financial and operating results, potential partnering transactions and sales targets, the company's regulatory strategies and timing and results of clinical studies, the potential benefits and mechanisms of action of the company's product and product candidates (including their potential as components of combination therapies and the timing and use of the net proceeds from the proposed offering).

The company's forward-looking statements are based on the estimates and assumptions of management as of the date of this presentation and are subject to risks and uncertainties that may cause the actual results to be materially different than those projected, such as risks related to delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective (including when our product candidates are studied in combination with other compounds), delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with third parties to discover, develop and commercialize products, risks associated with establishing and maintaining sales, marketing and distribution capabilities, and market conditions that may affect whether the offering will be made or consummated on the proposed terms, if at all.

Other risks affecting the company are described under the heading "Risk Factors" and elsewhere in the company's Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2016, and other periodic reports filed with the SEC.

Vision: Intestinal Targeting By Design

Build on a long-standing foundation of developing drugs for the lung





- Topical delivery to the organ of interest
- Maximal therapeutic benefit targeted directly at the disease area
- Negligible systemic absorption to minimize systemic side effects

Theravance Biopharma

Vision: Intestinal Targeting By Design

TPBH is transforming the conventional approach to oral JAK inhibition





- Adopts the same mindset as in respiratory disease
- Focuses on targeted maximal activity at the site of inflammation in the colonic wall
- Challenges the conventional approach to dosing oral JAK inhibitors

Theravance Biopharma

Vision: Intestinal Targeting By Design

Previous oral JAK inhibitors were designed to be systemically active

Tofacitinib (illustrative)



Organ	Drug levels
Small intestinal wall	Low
Portal vein	High
Systemic circulation	High
Large intestinal wall	Low
Stool	Minimal

Theravance Biopharma

Vision: Intestinal Targeting By Design

TD-1473 is designed to maximize local anti-inflammatory efficacy & minimize systemic exposure

Tofacitinib (illustrative)



Organ	Drug levels
Small intestinal wall	Low
Portal vein	High
Systemic circulation	High
Large intestinal wall	Low
Stool	Minimal

TD-1473 (illustrative)



Organ	Drug levels
Small intestinal wall	Moderate
Portal vein	Moderate
Systemic circulation	Minimal
Large intestinal wall	Moderate
Stool	Moderate

Theravance Biopharma

Efficacy of Tofacitinib JAK Inhibition Driven by Local Exposure

Preclinical PoC for maximizing therapeutic index with GI-restricted molecule





- Intracecal administration results in equivalent efficacy with 15-fold lower dose, similar colon concentration, and 80-fold lower plasma concentration

Shen *et al*. **Colon Targeted Delivery of Tofacitinib Inhibits Oxazolone-induced Colitis in Mice, Despite Low Systemic Exposure**. European Crohn's and Colitis Organisation Conference March 2016

Theravance Biopharma

TD-1473 Reduces Rodent Colitis without Systemic Immunosuppression

Differentiated from tofacitinib in the same preclinical models







- TD-1473 produces an anti-inflammatory effect at 10X lower dose & 1000X lower plasma concentration than tofacitinib
- TD-1473 shows no evidence of dose-dependent immunosuppressive effect, in contrast to tofacitinib

Beattie *et al*. **TD-1473, a Novel, Potent, and Orally Administered, GI-targeted, Pan-Janus Kinase (JAK) Inhibitor** . European Crohn's and Colitis Organisation Conference March 2016

Theravance Biopharma

In-vitro & Ex-vivo Biological Properties of TD-1473

Potent JAK Inhibitor in Biochemical, Cellular and Colon Tissue Assays

K_i or IC_{50} values in nM

Kinase domain

	JAK1	JAK2	JAK3	TYK2
TD-1473	0.1	0.1	1.6	0.3
tofacitinib	*0.8*	*0.6*	*0.3*	*13*

Epithelial

	IL-13 (JAK1/2) pSTAT6	IL-8
TD-1473	80	80
tofacitinib	*50*	*25*

T cell

	IL-2 (JAK1/3) pSTAT5	IFNγ	IL-6 (JAK1/2) pSTAT3	IFNα (JAK1/TYK2) pSTAT1	IL-12 (JAK2/TYK2) pSTAT4
TD-1473	32	63	158	32	126
tofacitinib	*25*	*32*	*126*	*32*	*1260*



Monocyte

	GM-CSF (JAK2) pSTAT5	IL-4 (JAK1/2) pSTAT6
TD-1473	200	32
tofacitinib	*126*	*40*



Human IBD colon

	IL-4 (JAK1/2) pSTAT6
TD-1473	100
tofacitinib	*50*



Mouse isolated colon (intraluminal drug dosing)

	IFN-g (JAK1/2) pSTAT1
TD-1473	3200
tofacitinib	*4000*

Theravance Biopharma

Disposition of TD-1473 in Rat

Optimized for Intestinal Restriction and Low Systemic Exposure

- TD-1473 is present at high levels in the lumen and tissue throughout the rat digestive tract
- Systemic levels of TD-1473 are low due to limited absorption and high clearance
- Corresponding tissue:plasma ratio (<40:1) and content:plasma ratio (<400:1) for tofacitinib are low relative to TD-1473



Theravance Biopharma

TD-1473 Phase I FIH Study Schema

Study 0140: Nested SAD/MAD in Healthy Volunteers



Primary Objective:

- To evaluate the safety and tolerability of TD-1473 in healthy subjects in single ascending doses (n=40) and 14-day multiple ascending doses (n=32)

Secondary Objective:

- To evaluate the pharmacokinetics of single ascending doses and multiple ascending doses of TD-1473 in plasma, urine and stool of healthy subjects

TD-1473 shows a favorable tolerability profile

A total of 476 patient-days of dosing

- TD-1473 was generally well tolerated as a single dose up to 1000mg and as multiple daily doses up to 300mg QD for 14 days
  - No serious, moderate, or severe AEs were reported in subjects dosed with TD-1473
  - There were no adverse events leading to study drug discontinuation
  - All treatment-emergent adverse events in subjects dosed with TD-1473 were mild in severity and short in duration
- Vital sign and ECG assessments did not demonstrate any clinically significant changes relative to placebo
- No clinically relevant changes in chemistry or hematology laboratory parameters relative to placebo

TD-1473 Single and Multiple Dose Plasma PK

PK profile is consistent with slow absorption throughout the length of the small and large intestine

Multiple Ascending Dose
PK on Day 14 (log scale)



Mean ± SD plotted

Multiple Ascending Dose
PK on Day 14 (normal scale)



- Dose-proportional exposures from 10 – 1000 mg
- TD-1473 appears rapidly in plasma with low systemic concentrations consistent with limited oral bioavailability
  - At steady state, the plasma exposures of TD-1473 at daily doses of 30 mg and 100 mg were approximately 75-fold and 15-fold lower, respectively, as compared to the plasma exposure of tofacitinib at twice daily doses of 10 mg
- High levels of TD-1473 present in stool at low doses, consistent with stool concentrations seen in positive preclinical models

Tofacitinib Comparison: Data Extracted from Dowty ME, et al. JPET 2014.

TBPH plans to progress TD-1473 to a patient study

Totality of evidence suggests a therapeutically relevant dose of TD-1473 can penetrate the colon wall with minimal release into the systemic circulation

- TBPH is encouraged by the evidence to date
  - Compelling preclinical evidence in relevant disease models
    - Demonstrates that systemic exposure is not a prerequisite
    - Confirms that TD-1473 achieves high mural concentrations
    - Low systemic exposures and no dose-related immunosuppression
  - Favorable PK and tolerability profile in healthy human volunteers
    - No serious adverse events following single or repeat dose administration
    - No clinically relevant changes in ECG, vitals or labs relative to placebo
    - Low systemic exposure even at multiples of the likely intended dose range
- TBPH will progress to a Phase 1b study in patients with moderately or severely active ulcerative colitis by end-2016

Theravance Biopharma

Medicines That Make a Difference®

Q&A

Theravance Biopharma

Medicines That Make a Difference®

Thank You